Delving into the Latest Updates on Human chorionic gonadotropin(IBSA) with Synapse

AbstractObjectiveHuman choriogonadotrophin (hCG) treatment of gonadotrophin‐deficient infertile men uses hCG of urinary (uhCG) or recombinant (rhCG) origin, but these treatments have not been compared nor are there studies defining rhCG dosing in men.DesignhCG products were studied in randomized cross‐over single‐dose studies of standard (Study 1, 1500 IU and 62.5 µg, respectively) or high (Study 2, 5000 IU and 250 µg) dose and a multi‐dose population pharmacology study of hCG use.ParticipantsEight (Study 1) and seven (Study 2) volunteers in cross‐over and 52 gonadotrophin‐deficient men in the multi‐dose studyMeasurementsIn cross‐over studies, serum testosterone (T), dihydrotestosterone (DHT) and estradiol by liquid chromatography‐mass spectrometry (LCMS) and serum hCG, LH, FSH, SHBG and T (observational study) by immunoassays.ResultsAfter standard and high‐dose injection, serum hCG and testosterone responses had similar timing and peak concentrations except for a mildly lower early (<48 h) serum testosterone with uhCG. In the multi‐dosing study, both hCGs had similar pharmacokinetics (pooled half‐life 5.8 days, p < .001), while serum testosterone concentrations were stable after injection and did not differ between hCG products. Bench testing verified that 20% of pens from 4/10 individuals were used inappropriately.ConclusionsAlthough hCG pharmacokinetics are not formally bioequivalent, the similar pharmacodynamic effects on serum testosterone indicate that at the doses tested both hCGs provide comparable clinical effects. The starting dose of rhCG for treating gonadotrophin‐deficient men should be 62.5 µg (6 clicks) of the rhCG pen.

01 Aug 2023·Transplantation and Cellular Therapy

Phase II, Open-Label Clinical Trial of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor for Life-Threatening Acute Graft-versus-Host Disease

Article

Author: Blazar, Bruce R ; Weisdorf, Daniel J ; Jurdi, Najla El ; Miller, Jeffrey S ; MacMillan, Margaret L ; Hoeschen, Andrea ; Maakaron, Joseph ; Rashidi, Armin ; Jacobson, Pamala A ; Ustun, Celalettin ; Holtan, Shernan G ; Wagner, John E ; Panoskaltsis-Mortari, Angela ; Cao, Qing ; Betts, Brian C

Treatments that aid inflammation resolution, immune tolerance, and epithelial repair may improve outcomes beyond high-dose corticosteroids and other broad immunosuppressants for life-threatening acute graft-versus-host disease (aGVHD). We studied the addition of urinary-derived human chorionic gonadotropin/epidermal growth factor (uhCG/EGF; Pregnyl; Organon, Jersey City, NJ) to standard aGVHD therapy in a prospective Phase II clinical trial (ClinicalTrials.gov identifier NCT02525029). Twenty-two patients with Minnesota (MN) high-risk aGVHD received methylprednisolone 48 mg/m²/day plus 2000 units/m² of uhCG/EGF s.c. every other day for 1 week. Patients requiring second-line aGVHD therapy received uhCG/EGF 2000 to 5000 units/m² s.c. every other day for 2 weeks plus standard of care immunosuppression (physician's choice). Responding patients were eligible to receive maintenance doses twice weekly for 5 weeks. Immune cell subsets in peripheral blood were evaluated by mass cytometry and correlated with plasma amphiregulin (AREG) level and response to therapy. Most patients had stage 3-4 lower gastrointestinal tract GVHD (52%) and overall grade III-IV aGVHD (75%) at time of enrollment. The overall proportion of patients with a response at day 28 (primary endpoint) was 68% (57% with complete response, 11% with partial response). Nonresponders had higher baseline counts of KLRG1⁺ CD8 cells and T cell subsets expressing TIM-3. Plasma AREG levels remained persistently elevated in nonresponders and correlated with AREG expression on peripheral blood T cells and plasmablasts. The addition of uhCG/EGF to standard therapy is a feasible supportive care measure for patients with life-threatening aGVHD. As a commercially available, safe, and inexpensive drug, uhCG/EGF added to standard therapy may reduce morbidity and mortality from severe aGVHD and merits further study.

01 Mar 2022·Clinical Drug Investigation

Randomized Pharmacokinetic Study of a Highly Purified Human Chorionic Gonadotropin and of a Recombinant Human Chorionic Gonadotropin Following Single Subcutaneous Administration in Healthy Women

Article

Author: Leuratti, Chiara ; Radicioni, Milko ; Cometti, Barbara

BACKGROUND AND OBJECTIVESExogenous human chorionic gonadotropin (hCG) acts on the final phase of the follicle maturation. Choriomon^®, a highly purified hCG formulation, is approved in many European and extra-European countries for the induction of ovulation after stimulation of follicular development. The present study compares hCG bioavailability of Choriomon^® (Test product) versus a recombinant hCG preparation (Ovitrelle^®; Reference product).METHODSIn this randomized, two-way cross-over study, 26 healthy women received a single dose of Choriomon^® (10,000 IU) and Ovitrelle^® (250 µg; 6500 IU) by subcutaneous injection. hCG was determined in serum up to 192 h post-dose. Dose-normalized peak concentration (C_max) and area under the concentration-time curve up to the time of the last quantifiable concentration (AUC_0-t) and extrapolated to infinity (AUC_0-∞) were calculated and compared between the two treatments.RESULTSSerum hCG concentrations increased rapidly with a very similar pharmacokinetic curve for the two products. The test/reference geometric means ratio (GMR) for AUC_0-t and AUC_0-∞ corresponded to 121.31 and 119.81%, and the upper limits of the 90% confidence intervals (CIs) (130.21% and 128.51%, for AUC_0-t and AUC_0-∞, respectively) exceeded the 125% bioequivalence threshold. C_max GMR was 146.89%, indicating a rate of hCG absorption approximately 50% greater for the test product (90% CI 132.30-163.10). Half-life (t_1/2) was very similar (36.77 ± 5.11 h and 38.63 ± 6.08 h), whereas time to achieve C_max (t_max) significantly differed, with median values of 16 h and 24 h for Choriomon^® and Ovitrelle^®, respectively, (p = 0.0023).CONCLUSIONSThe differences between Choriomon^® and Ovitrelle^® pharmacokinetic parameters can be ascribed to the different raw source of the products and are reflected in the approved dose regimens of the two hCG formulations. The observed lack of bioequivalence between the two compounds at the given doses is not clinically relevant, as results from Phase III studies indicated similar clinical efficacy and safety. The safety data are in line with the known safety profile of the two products.CLINICALTRIALSGOV REGISTRATION NONCT03735030.

100 Deals associated with Human chorionic gonadotropin(IBSA)

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Infertility	-	IBSA Institut Biochimique SA	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ovarian Stimulations	Phase 1	Canada	IBSA Institut Biochimique SA	15 Sep 2024
Abortion, Spontaneous	Discovery	Iran	Royan Institute	30 Nov 2015
Ovarian Hyperstimulation Syndrome	Discovery	Egypt	Cairo University	30 Jun 2015
Endometriosis	Discovery	Egypt	Cairo University	01 Jun 2015
Infertility, Male	Discovery	Egypt	Cairo University	01 Jun 2015
Infertility	Discovery	Switzerland	IBSA Institut Biochimique SA	01 Aug 2005

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data